Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/28/2026 | Mkt Perform | William Blair | |
| 1/29/2026 | $400.00 | Equal-Weight → Overweight | Morgan Stanley |
| 1/22/2026 | $440.00 | Hold → Buy | Jefferies |
| 12/9/2025 | $400.00 | Overweight | Barclays |
| 6/3/2025 | $337.00 | Equal Weight → Overweight | Wells Fargo |
| 12/4/2024 | $280.00 | Outperform | Mizuho |
| 9/18/2024 | $275.00 → $245.00 | Buy → Neutral | BofA Securities |
| 2/26/2024 | $261.00 | Outperform | Leerink Partners |
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
8-K - Cencora, Inc. (0001140859) (Filer)
SD - Cencora, Inc. (0001140859) (Filer)
10-Q - Cencora, Inc. (0001140859) (Filer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
William Blair initiated coverage of Cencora with a rating of Mkt Perform
Morgan Stanley upgraded Cencora from Equal-Weight to Overweight and set a new price target of $400.00
Jefferies upgraded Cencora from Hold to Buy and set a new price target of $440.00
Cencora reaffirms fiscal 2026 and long-term financial guidance Cencora, Inc. (NYSE:COR) today announced Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of the Company, effective June 29, 2026. Ms. Boratto succeeds James F. Cleary, who will be retiring from his role as Executive Vice President and Chief Financial Officer as previously announced. Mr. Cleary will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition. Ms. Boratto is an experienced public company executive with considerable financial and operational experience across the healthcare and consumer sectors. She most recently served as Chief Financial Offic
Cencora reaffirms fiscal 2026 financial guidance Cencora, Inc. (NYSE:COR) today announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer effective June 30, 2026. Cencora has engaged an executive search firm to identify and evaluate potential successors from internal and external candidates. Mr. Cleary will assist in the search process and will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition. Mr. Cleary, 62, has served as Cencora's CFO since November 2018. He joined the Company in February 2015, following its acquisition of MWI Veterinary Supply, where he had served as Chief Executive Officer for over a de
Cencora, Inc. (NYSE:COR) today announced that its Board of Directors has appointed Lead Independent Director D. Mark Durcan as Chairman of the Board of Directors, effective October 1, 2025. Mr. Durcan will succeed Steven H. Collis, who has served as Cencora's Chairman since 2016 and previously served as Cencora's Chief Executive Officer from 2011 until 2024. As previously disclosed, Mr. Collis was elected to serve as Executive Chairman of the Board effective October 1, 2024 for a period of one year. "Our Board is confident that Mark's public company CEO and board experience, along with his strategic planning and technological innovation experience, make him the right person to step into t
Revenue of $78.4 billion for the Second Quarter, a 3.8 percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $8.40 and Adjusted Diluted EPS of $4.75 Adjusted Diluted EPS Guidance Range Raised to $17.65 to $17.90 for Fiscal 2026 Cencora Expects to Repurchase $1 Billion in Shares by the End of Calendar 2026 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2026 second quarter ended March 31, 2026, revenue increased 3.8 percent year-over-year to $78.4 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $8.40 for the second quarter of fiscal 2026 compared to $3.68 in the prior year second quarter. Adjus
Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2026 on Wednesday, May 6, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 6, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the call v
Revenue of $85.9 billion for the First Quarter, a 5.5% Increase Year-Over-Year First Quarter GAAP Diluted EPS of $2.87 and Adjusted Diluted EPS of $4.08 Adjusted Operating Income Guidance Raised to Growth of 11.5% to 13.5% Adjusted Diluted EPS Guidance Range Reaffirmed at $17.45 to $17.75 for Fiscal 2026 Company Completes Acquisition of OneOncology Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2026 first quarter ended December 31, 2025, revenue increased 5.5 percent year-over-year to $85.9 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.87 for the first quarter of fiscal 2026 compared to $2.50 in th
SC 13G/A - Cencora, Inc. (0001140859) (Subject)
SC 13D/A - Cencora, Inc. (0001140859) (Subject)
SC 13G/A - CoreSite Realty Corp (0001490892) (Subject)
Cencora reaffirms fiscal 2026 and long-term financial guidance Cencora, Inc. (NYSE:COR) today announced Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of the Company, effective June 29, 2026. Ms. Boratto succeeds James F. Cleary, who will be retiring from his role as Executive Vice President and Chief Financial Officer as previously announced. Mr. Cleary will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition. Ms. Boratto is an experienced public company executive with considerable financial and operational experience across the healthcare and consumer sectors. She most recently served as Chief Financial Offic
The Board of Directors authorized a new $2.0 billion share repurchase program Cencora, Inc. (NYSE:COR) today updated its fiscal year 2026 financial guidance as a result of recent opportunistic share repurchases. Cencora now expects adjusted diluted earnings per share to be in the range of $17.70 to $17.90, up from the previous range of $17.65 to $17.90. The opportunistic share repurchases completed in May align with the Company's previously disclosed expectation that it will repurchase $1.0 billion in shares of common stock by the end of calendar 2026. The Company will be participating in upcoming investor discussions in which the updated outlook for fiscal year 2026 will be discussed.
Revenue of $78.4 billion for the Second Quarter, a 3.8 percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $8.40 and Adjusted Diluted EPS of $4.75 Adjusted Diluted EPS Guidance Range Raised to $17.65 to $17.90 for Fiscal 2026 Cencora Expects to Repurchase $1 Billion in Shares by the End of Calendar 2026 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2026 second quarter ended March 31, 2026, revenue increased 3.8 percent year-over-year to $78.4 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $8.40 for the second quarter of fiscal 2026 compared to $3.68 in the prior year second quarter. Adjus